Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- PMDA Committee to Offer Proposals to Shorten Pre-review Period
May 23, 2011
- Achieving CO2 Emissions Target to Remain Priority in FY2011: JPMA
May 23, 2011
- PMDA Introduces 12-Team System to Evaluate ADR Information
May 23, 2011
- Foreign-affiliated Drug Companies Outgrow the Market in Japan
May 23, 2011
- Lurasidone Fails to Show Efficacy in Pan-Asia PIII Study: DSP
May 23, 2011
- Top-4 Wholesalers' Operating Profit Rate Falls Below “Worst-ever”Levels Recorded 2 Years Ago
May 23, 2011
- Mucosta Superior to Hyaluronate in Improving Conjunctival Damage: Otsuka
May 23, 2011
- Operating Profits Down 60% for Ethical Drugs Wholesale Business: Medipal HD
May 23, 2011
- Dabigatran Superior to Warfarin Regardless of Stroke Risk: BI
May 23, 2011
- Alfresa HD: Double-digit Decline in Profits Despite Higher Sales
May 23, 2011
- Tofacitinib for RA Meets Primary Endpoints in PIII: Pfizer
May 23, 2011
- METI to Subsidize Installation of In-house Power Generators
May 16, 2011
- Simponi Recommended for Approval
May 16, 2011
- FDA Issues Complete Response Letter for Aricept Patch: Eisai
May 16, 2011
- Major Drugstore Chains to Hire More New Graduates from Disaster Areas
May 16, 2011
- Kyowa Kirin Files NDA for Anti-CCR4 Antibody KW-0761
May 16, 2011
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…